Epidemiology and Risk Factors of Alzheimer’s Disease in Iran: A Systematic Review
Background: Alzheimer's disease is a chronic disease characterized by a progressive decline in mental abilities and quality of life alongside behavioral abnormalities associated with high economic burden. The purpose of this study was to investigate epidemiology and risk factors of Alzheimer’s disease in Iran.
Methods: In this systematic review study, both Persian and English-language databases including Medline, Google Scholar, PubMed, web of science and Magiran were searched using following keywords: epidemiology, Alzheimer, dementia and Iran without time limit up to 2017. Thirty articles abstract out of 50 studies related to this topics, were reviewed. Of which 12 full text entered into the quality assessment process and finally, four articles were selected for inclusion in this study and their results was extracted.
Results: The total sample size of the 4 selected studies was 2781. The prevalence of Alzheimer's disease in the current study was estimated to be 2.3% in the population of 67-78 years old. Age, genetics, depression and hypertension were determined as the risk factors for Alzheimer's disease, while daily listening to music, meeting weekly with friends and daily intake of vitamin E were considered as the factors with protective role in this disease.
Conclusion: Alzheimer's disease is one of the main causes of functional dependence and mortality in the elderly people. Lifestyle changes and multiple mental activities in elderly increases the cognitive ability of these population, which will reduce direct and indirect costs of this disease.
2. Anonymus (2007). Chronic disorders and qaulity of life in older adults. In: Aging and chronic disorders. Eds, Morewitz SJ, Goldstein ML. Springer, Boston, MA. pp.28-34 (chapter three).
3. Alzheimer’s Association (2015). 2015 Alzheimer's disease facts and figures. Alzheimers Dement, 11(3):332-84.
4. Mayeux R, Stern Y(2012). Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med, 2(8):a006239.
5. Aisen PS, Cummings J, Schneider LS (2012). Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med, 2(3):a006395.
6. Zali H, Samaneh Sadat S, Rashidy Pour A et al (2015). Epidemiology and etiology of Alzheimer's disease. Koomesh, 16 (2):119-27.
7. Yiannopoulou KG, Papageorgiou SG (2013). Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord, 6 (1):19-33
8. Tedeschi G, Cirillo M, Tessitore A, Cirillo S(2008) .Alzheimer’s disease and other dementing conditions. Neurol Sci, 29 Suppl 3:301-7.
9. Aevarsson O, Skoog I (1996). A Population‐Based Study on the Incidence of Dementia Disorders Between 85 and 88 Years of Age. J Am Geriatr Soc, 44 (12):1455-60.
10. Sabayan B, Bonneux L(2011). Dementia in Iran: how soon it becomes late!. Arch Iran Med, 14 (4):290-291
11. Saifadini R, Tajadini H, Choopani R et al (2016). Perception of Alzheimer disease in Iranian traditional medicine. Iran Red Crescent Med J,18 (3): e22054.
12. Mohammadi M-R, Davidian H, Noorbala AA, et al (2005). An epidemiological survey of psychiatric disorders in Iran. Clin Pract Epidemiol Ment Health, 1:16.
13. Anonymous (2002). Active Ageing: a policy framework, World Health Organization. Noncommunicable Diseases and Mental Health Cluster. Noncommunicable Disease Prevention and Health Promotion Department. Ageing and Life Course, Second United Nations World Assembly on Ageing, Madrid, Spain. https://extranet.who.int/agefriendlyworld/wp-content/uploads/2014/06/WHO-Active-Ageing-Framework.pdf
14. From the Centers for Disease Control and Prevention (2003). Public health and aging: trends in aging--United States and worldwide. JAMA, 289:1371-3.
15. Kinsella K, Velkoff VA (2002). The demographics of aging. Aging Clin Exp Res,14 (3):159-69.
16. Hall CB, Verghese J, Sliwinski M, et al (2005). Dementia incidence may increase more slowly after age 90 Results from the Bronx Aging Study. Neurology,65 (6):882-6.
17. Kalaria RN, Maestre GE, Arizaga R, et al (2008). Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol, 7 (9): 812-26.
18. Raygani AV, Zahrai M, Raygani AV, et al (2005). Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran. Neurosci Lett, 375 (1):1-6.
19. Foroughan M, Farahani ZG, Shariatpanahi M, et al (2008). Risk factors of Alzheimer's disease among Iranian population. Curr Alzheimer Res, 5 (1):70-2.
20. Khorram Khorshid HR, Manoochehri M, Nasehi L et al (2012). Ccr2-64i and Ccr5 Δ32 Polymorphisms in Patients with Late-Onset Alzheimer’s disease; A Study from Iran (Ccr2-64i And Ccr5 Δ32 Polymorphisms in Alzheimer’s disease). Iran J Basic Med Sci,15 (4):937-944.
21. Gholamzadeh S, Heshmati B, Mani A et al (2017). The Prevalence of Alzheimer’s Disease; its Risk and Protective Factors Among the Elderly Population in Iran. Shiraz E-Medical Journal, 18 (9): e57576.
22. Prince M, Jackson J (2012). World Alzheimer report 2009. Alzheimer’s Disease International. London. 2009. pp.5-12. https://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf
23. Ott A, Breteler MM, Van Harskamp F, et al (1995). Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ,310 (6985):970-3.
24. Querfurth HW, Laferla FM (2010). Alzheimer's disease reply. N Engl J Med,362 (19):1844-5.
25. Holtzman DM, Morris JC, Goate AM (2011). Alzheimer’s disease: the challenge of the second century. Sci Transl Med, 3(77):77sr1.
26. Noroozian M (2012). The elderly population in iran: an ever growing concern in the health system. Iran J Psychiatry Behav Sci, 6 (2):1-6.
27. Hazar N, Seddigh L, Rampisheh Z, Nojomi M (2016). Population attributable fraction of modifiable risk factors for Alzheimer disease: A systematic review of systematic reviews. Iran J Neurol,15 (3):164-72.
28. Xu W, Tan L, Wang HF, et al(2015). Meta-analysis of modifiable risk factors for Alzheimer's disease. J Neurol Neurosurg Psychiatry, 86 (12):1299-306.
29. Stern Y (2012). Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol,11(11):1006-12.